{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:19:37Z","timestamp":1792279177228,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40261-021-01093-8","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T09:03:06Z","timestamp":1635843786000},"page":"1099-1107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Subcutaneous Infliximab, CT-P13\u00a0SC: A Profile of Its Use in the EU"],"prefix":"10.1007","volume":"41","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"1093_CR1","unstructured":"European Medicines Agency. Remicade (infliximab): summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf. Accessed 04 Oct 2021."},{"issue":"3","key":"1093_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40259-014-0094-1","volume":"28","author":"K McKeage","year":"2014","unstructured":"McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs. 2014;28(3):313\u201321.","journal-title":"BioDrugs"},{"issue":"5","key":"1093_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40259-016-0193-2","volume":"30","author":"HA Blair","year":"2016","unstructured":"Blair HA, Deeks ED. Infliximab biosimilar (CT-P13; infliximab-dyyb): a review in autoimmune inflammatory diseases. BioDrugs. 2016;30(5):469\u201380.","journal-title":"BioDrugs"},{"issue":"5","key":"1093_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40259-017-0240-7","volume":"31","author":"YN Lamb","year":"2017","unstructured":"Lamb YN, Scott LJ, Deeks ED. SB2: an infliximab biosimilar. BioDrugs. 2017;31(5):461\u20134.","journal-title":"BioDrugs"},{"issue":"6","key":"1093_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40259-018-0310-5","volume":"32","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT. PF-06438179\/GP1111: an infliximab biosimilar. BioDrugs. 2018;32(6):639\u201342.","journal-title":"BioDrugs"},{"key":"1093_CR6","unstructured":"European Medicines Agency. Remsima: summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/documents\/product-information\/remsima-epar-product-information_en.pdf. Accessed 04 Oct 2021."},{"key":"1093_CR7","unstructured":"European Medicines Agency. Flixabi: summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/documents\/product-information\/flixabi-epar-product-information_en.pdf. Accessed 04 Oct 2021."},{"key":"1093_CR8","unstructured":"European Medicines Agency. Zessly: summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/documents\/product-information\/zessly-epar-product-information_en.pdf. Accessed 04 Oct 2021."},{"issue":"5","key":"1093_CR9","first-page":"847","volume":"33","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Houssiau F, Joly J, et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. J Rheumatol. 2006;33(5):847\u201353.","journal-title":"J Rheumatol"},{"key":"1093_CR10","unstructured":"European Medicines Agency. Remsima (infliximab): summary of opinion (post authorisation). 2019. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-remsima-x-62_en.pdf. Accessed 04 Oct 2021."},{"key":"1093_CR11","unstructured":"European Medicines Agency. Remsima (infliximab): summary of opinion (post authorisation). 2020. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-remsima-ii\/82_en.pdf. Accessed 04 Oct 2021."},{"issue":"8","key":"1093_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","volume":"57","author":"A Hemperly","year":"2018","unstructured":"Hemperly A, Vande CN. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57(8):929\u201342.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1093_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00063030-200216020-00005","volume":"16","author":"GM Keating","year":"2002","unstructured":"Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn\u2019s disease and rheumatoid arthritis. BioDrugs. 2002;16(2):111\u201348.","journal-title":"BioDrugs"},{"issue":"7","key":"1093_CR14","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous versus intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340\u201353.","journal-title":"Gastroenterology"},{"issue":"5","key":"1093_CR15","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","volume":"60","author":"R Westhovens","year":"2020","unstructured":"Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial. Rheumatology (Oxford). 2020;60(5):2277\u201387.","journal-title":"Rheumatology (Oxford)"},{"key":"1093_CR16","unstructured":"European Medicines Agency. Remsima: extension of indication variation assessment report. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/remsima-h-c-2576-ii-0082-epar-assessment-report-variation_en.pdf. Accessed 04 Oct 2021."},{"issue":"15","key":"1093_CR17","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.2165\/00003495-200565150-00014","volume":"65","author":"MA Siddiqui","year":"2005","unstructured":"Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn\u2019s disease and rheumatoid arthritis. Drugs. 2005;65(15):2179\u2013208.","journal-title":"Drugs"},{"issue":"6","key":"1093_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.10302","volume":"46","author":"EW St Clair","year":"2002","unstructured":"St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2002;46(6):1451\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1093_CR19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1093_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13075-021-02487-x","volume":"23","author":"B Combe","year":"2021","unstructured":"Combe B, Allanore Y, Alten R, et al. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. Arthritis Res Ther. 2021;23(1):119.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1093_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/1744666X.2020.1858803","volume":"17","author":"R Caporali","year":"2021","unstructured":"Caporali R, Allanore Y, Alten R, et al. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Rev Clin Immunol. 2021;17(1):85\u201399.","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01093-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T15:26:51Z","timestamp":1637940411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01093-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01093-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"13 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}